Core Viewpoint - SOHM, Inc. has released a technical white paper on ABBIE, a novel Cas9-guided integrase platform that facilitates donor-DNA integration without causing double-strand breaks or the use of viral vectors [1] Company Overview - SOHM, Inc. is a pharmaceutical and biotechnology company that specializes in generic drugs and gene-editing tools, positioning itself as a leader in Gene Editing and Cell Engineering [1] Product Development - The company has established SKOV3-GYS1, an ovarian cancer cell line that exhibits stable overexpression of glycogen synthase 1 (GYS1), aimed at supporting drug-discovery applications related to glycogen metabolism [1]